Nonclinical safety strategies for stem cell therapies

被引:44
|
作者
Sharpe, Michaela E. [1 ]
Morton, Daniel [2 ]
Rossi, Annamaria [1 ]
机构
[1] Pfizer Ltd, Drug Safety Res & Dev, Investigat Toxicol, Sandwich CT13 9NJ, Kent, England
[2] Pfizer Inc, Drug Safety Res & Dev, Exploratory Drug Safety, Cambridge, MA 02140 USA
关键词
Stem cells; Biodistribution; Immunogenicity; Tumorigenicity; Toxicology; Safety studies; HUMAN BONE-MARROW; PROGENITOR CELLS; IMMUNOLOGICAL-PROPERTIES; TERATOMA FORMATION; CLINICAL-TRIALS; STROMAL CELLS; TRANSPLANTATION; ENGRAFTMENT; EXPRESSION; DIFFERENTIATION;
D O I
10.1016/j.taap.2012.05.007
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Recent breakthroughs in stem cell biology, especially the development of the induced pluripotent stem cell techniques, have generated tremendous enthusiasm and efforts to explore the therapeutic potential of stem cells in regenerative medicine. Stem cell therapies are being considered for the treatment of degenerative diseases, inflammatory conditions, cancer and repair of damaged tissue. The safety of a stem cell therapy depends on many factors including the type of cell therapy, the differentiation status and proliferation capacity of the cells, the route of administration, the intended clinical location, long term survival of the product and/or engraftment, the need for repeated administration, the disease to be treated and the age of the population. Understanding the product profile of the intended therapy is crucial to the development of the non-clinical safety study design. (C) 2012 Elsevier Inc. All rights reserved.
引用
收藏
页码:223 / 231
页数:9
相关论文
共 50 条
  • [21] Unlikely stem cell therapies
    Condic, Maureen
    NATURE NEUROSCIENCE, 2007, 10 (07) : 803 - 803
  • [22] Stem cell therapies in the clinic
    Acharya, Shrinivas
    Shaha, Suyog
    Bibbey, Michael Griffith
    Mukherji, Malini
    Zhao, Zongmin
    Mitragotri, Samir
    BIOENGINEERING & TRANSLATIONAL MEDICINE, 2025,
  • [23] Gene and stem cell therapies
    Kaji, EH
    Leiden, JM
    JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (05): : 545 - 550
  • [24] Unlikely stem cell therapies
    Maureen Condic
    Nature Neuroscience, 2007, 10 : 803 - 803
  • [25] Shortcut for stem cell therapies
    不详
    SCIENCE, 2016, 354 (6318) : 1356 - 1357
  • [26] Stem cell therapies: heart
    Ellison, Georgina
    HUMAN GENE THERAPY, 2013, 24 (05) : A12 - A12
  • [27] The safety of drug therapies: strategies and instruments for nurses
    Festini, Filippo
    Sperotto, Sara
    Neri, Stella
    ASSISTENZA INFERMIERISTICA E RICERCA, 2007, 26 (03) : 165 - 180
  • [28] New Strategies and In Vivo Monitoring Methods for Stem Cell-Based Anticancer Therapies
    Wang, Ping
    Aguirre, Aitor
    STEM CELLS INTERNATIONAL, 2018, 2018
  • [29] Stem cell therapies in stroke rehabilitation: a narrative review of current strategies and future prospects
    Aderinto, Nicholas
    Olatunji, Gbolahan
    Kokori, Emmanuel
    Babalola, Adetola Emmanuel
    Yusuf, Ismaila Ajayi
    Apampa, Oluwatobiloba Oluwatomisin
    Ukoaka, Bonaventure Michael
    Aboje, John Ehi
    Adefusi, Temiloluwa
    Moradeyo, Abdulrahmon
    Obasanjo, Opabode Muntaqim
    Ogieuhi, Ikponmwosa Jude
    Omoworare, Oluwatobi
    Olatunji, Doyin
    EGYPTIAN JOURNAL OF NEUROLOGY PSYCHIATRY AND NEUROSURGERY, 2024, 60 (01):
  • [30] Revolutionizing the treatment for nasopharyngeal cancer: the impact, challenges and strategies of stem cell and genetically engineered cell therapies
    Looi, Chin-King
    Loo, Ee-Mun
    Lim, Heng-Chee
    Chew, Yik-Ling
    Chin, Kok-Yong
    Cheah, Shiau-Chuen
    Goh, Bey Hing
    Mai, Chun-Wai
    FRONTIERS IN IMMUNOLOGY, 2024, 15